Mark Law, MD
Ophthalmology · Newark, OHNPI 1275536237
Payments from drug & device makers
Across 169 payments — averaging $44.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$1K
- AbbVie$1K
- Alcon$876
- Regeneron Healthcare Solutions, Inc.$725
- Mallinckrodt Hospital Products Inc.$555
- Tarsus Pharmaceuticals, Inc.$492
- plus $3K from 20 others
What the payments were for
- Travel & lodging$89512%
- Food & beverage$6,61788%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 7 | $1,217 |
| AbbVie(2 entities) | 38 | $1,021 |
| Alcon | 18 | $876 |
| Regeneron Healthcare Solutions, Inc. | 17 | $725 |
| Mallinckrodt Hospital Products Inc. | 15 | $555 |
| Tarsus Pharmaceuticals, Inc. | 13 | $492 |
| Bausch & Lomb Americas Inc. | 5 | $388 |
| Dompe US, Inc. | 3 | $324 |
| Amgen(2 entities) | 4 | $269 |
| NEW World Medical,inc. | 10 | $239 |
| Oyster Point Pharma, Inc. | 3 | $233 |
| Genentech USA, Inc. | 4 | $215 |
| Novartis | 9 | $179 |
| Aerie Pharmaceuticals, Inc. | 5 | $168 |
| Astellas Pharma US Inc | 1 | $121 |
| Ocular Therapeutix, Inc. | 1 | $106 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Rayner Intraocular Lenses Limited | 4 | $81 |
| Apellis Pharmaceuticals, Inc. | 2 | $45 |
| Sight Sciences, Inc. | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 2 | $30 |
| Biotissue Holdings Inc. | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Thea Pharma Inc. | 1 | $16 |
| Omeros Corporation | 1 | $16 |
| Harrow Eye, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Premium Cataract IOLs$1,137
- ACTHAR$363
- Oxervate$305
- XDEMVY$251
- TEPEZZA$234
- SUSVIMO$145
- Clareon PanOptix Pro$143
- Kahook Dual Blade$141
- Clearpath$141
- Ahmed Glaucoma Valve$141
- Streamline$141
- OZURDEX$125
- MIEBO$125
- XIIDRA$125
- VYZULTA$124
- AcrySof IQ VIVITY$124
- AcrySof IQ PanOptix UV IOL$124
- TYRVAYA$122
- Izervay$121
- EYLEA HD$121
How this compares
$7,512 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 65 | $34,605 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $14,176 |
| Travoprost | 73 | $12,223 |
| VyzultaLatanoprostene Bunod | 23 | $11,426 |
| XiidraLifitegrast | 14 | $10,774 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $6,603 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $6,368 |
| Latanoprost | 713 | $5,250 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $4,046 |
| Alphagan PBrimonidine Tartrate | 14 | $2,599 |
| Timolol Maleate | 241 | $2,093 |
| ErythromycinErythromycin Base | 222 | $1,802 |
| Brimonidine Tartrate | 157 | $1,748 |
| Prednisolone Acetate | 36 | $1,466 |
| Ketorolac Tromethamine | 57 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $1,021 | $51,379111 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $388 | $22,20037 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $168 | $6,60314 claims |
| AlconSimbrinza | $876 | $6,36824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Newark
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
- Jonathan LassCleveland$1.9M
- William WileyCleveland$1.9M
- Peter KaiserCleveland$1.5M
- David RogersColumbus$1.5M
- Michael SnyderCincinnati$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.